Refine by
Tissue Damage Technology
9 companies found
Technologybased inParis, FRANCE
TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: To reconstruct damaged tissue and restore its natural function. Our mission is to disrupt the field of surgery and ...
Technologybased inSalt Lake City, UTAH (USA)
3Helix develops and markets a novel collagen targeting technology, providing scientists and clinicians with new tools to investigate collagen pathology and to develop diagnostics and therapeutics for diseases with high collagen remodeling ...
The collagen hybridizing peptide (CHP) is a novel and unique peptide that specifically binds unfolded collagen chains, both in vitro and in vivo.[1,2,3] By sharing the Gly-X-Y repeating sequence of natural collagen, CHP has a strong capability to ...
Technologybased inGaithersburg, MASSACHUSETTS (USA)
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly ...
The current standard of care for autoimmune diseases is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and maligancies. Our approach to autoimmune disease is designed to ...
Technologybased inKiel, GERMANY
tiakis biotech AG (“tiakis”) – formerly Proteo Biotech AG - is the next generation preventive therapeutic technology company. We focus on our clinical-stage proprietary and pioneering tissue protective drug ...
Technologybased inHolliston, MASSACHUSETTS (USA)
HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases. The patient’s stem ...
Technologybased inLabège, FRANCE
Vaiomer microbiome studies and expert service supports your discoveries and innovations when identifying predictors and mechanisms associated with the development of chronic diseases. Vaiomer challenges the frontiers of microbiome research by ...
Bacterial translocation: the missing link between intestinal microbiome and human complex non-communicable diseases. Complex disorders are multifactorial and often chronic, caused by genetic and environmental factors and comprising hundreds of ...
Technologybased inChino, CALIFORNIA (USA)
Our mission at Specialty Enzymes & Probiotics is to improve the well-being of families across the globe, helping you bring people and their pets natural, efficacious ingredients to promote systemic, gut and immune health. We are enzyme pioneers in ...
Technologybased inMiami, FLORIDA (USA)
We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B, which is derived from culture-expanded medicinal signaling cells (MSCs) ...
Lomecel-B is made from special living cells called Medicinal Signaling Cells, or MSCs that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Because the cells come from another individual, Lomecel-B is ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Aspect Biosystems is a privately held biotechnology company combining the power of microfluidics and 3D bioprinting to fuel medical research and the development of bioprinted therapeutics. By adopting Aspect™s microfluidic 3D bioprinting platform ...
Accurately recreate complex and functional physiological structures for medical research, therapeutic discovery and regenerative medicine using the Aspect ...